Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,310.00down ₹0.90 (0.07%)BSE ₹1,305.00
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,310.90.
27 Oct: open ₹1,309.00, high ₹1,323.70, low ₹1,299.40
52-week range of traded prices to 27 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,09,343 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.05
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.82
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 22,01,00247.3% delivered
Dr. Reddy's Laboratories record dates, bonuses and splits
14 filed, newest first.
May 2025
Oct 2024
Jul 2024
May 2023
May 2022
May 2021
Jun 2020
Feb 2014
Feb 2013
18 Feb · Corporate action
Dr. Reddy's Laboratories Limited has informed the Exchange that the Board of Directors has fixed February 22, 2013 as record date for the purpose of ascertaining the debenture holder's entitlement to receive the second year's interest, at the rate of 9.25% per annum, on Non-convertible Debentures (NCDs) of the Company due for payment on March 24, 2013. The said interest on NCDs will be credited/paid on March 24, 2013.
Feb 2012
6 Feb · Corporate action
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors has fixed February 24, 2012 as record date for the purpose of ascertaing the debenture holders' entitlement to receive the 1st year's interest, at the rate of 9.25% per annum, On Non-convertible Debentures (NCDs) of the Company due for payment on March 24, 2012. The said interest on NCDs will be credited/ paid on March 24, 2012.
Mar 2011
9 Mar · Corporate action
Dr. Reddy'S Laboratories Limited has informed the Exchange that March 18, 2011 has been fixed as "Record Date" for determining the shareholders of the Company who will be entitled to receive 6(six) fully paid unsecured redeemable non-convertible bonus debentures of Rs.5/- each for every existing fully paid equity share of Rs.5/- each of the Company (bonus debentures) pursuant to the Scheme of Arrangement sanctioned by the Hon'ble High Court of Judicature, Andhra Pradesh at Hyderabad on July 19, 2010 which has come into effect on February 01, 2011.The Board of Directors has also fixed 9.25% as the coupon rate on these debentures, payable annually. These debentures would be redeemable, at par, at the end of 36 months from the date of allotment.
Mar 2010
31 Mar · Corporate action
Dr. Reddy's Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on March 31, 2010, considered and approved the proposal for issuance of bonus debentures to shareholders of the Company from its General Reserves built from undistributed profits in terms of a scheme of arrangement under Sections 391-394 and other relevant provisions of the Companies Act, 1956 ("Scheme").The proposed Scheme provides that subject to necessary approvals, the Company would issue, upon effectiveness of the Scheme, unsecured, non-convertible, redeemable, fully paid up bonus debentures of the face value of Rs. 5/- each ("Bonus Debentures") to its shareholders on the record date to be determined by the board of directors, in the ratio of 6 Bonus Debentures for every 1 equity share of Rs. 5/- each held by a member of the Company. The draft Scheme was also approved by the Board of Directors at the meeting. The Bonus Debentures would carry a coupon rate to be determined by the board of directors, payable annually and would be redeemable at par at the end of thirty six months from the date of allotment. The Bonus Debentures are proposed to be rated and listed. The issue and allotment of debentures will account for an amount not exceeding Rs. 520 Crores. The above proposal is subject to the satisfaction of various conditions, including obtaining necessary approvals from the shareholders and regulatory authorities including those of the stock exchanges under the Listing Agreement, Reserve Bank of India and sanction of the scheme of arrangement by the High Court of Andhra Pradesh. Further, the Company has submitted to the Exchange a copy of Press Release dated March 31, 2010 titled "Dr. Reddy's board approves bonus debentures issue". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
18 Jun · Corporate action
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The register of members and transfer register of the Company would remain closed from July 10 to July 14, 2007 (both days inclusive) for the purpose of payment of Dividend for the year 2006-07".